The German pharmaceutical company BioNTech expects that it will be possible to start the vaccination of residents of Germany against the new coronavirus at the beginning of next year. This was announced in an interview with the Suddeutsche Zeitung on Friday by investors Thomas Stryungmann and Michael Mochmann, who have been financing the Mainz-based firm since its inception.
вЂњWe hope that at the beginning of 2021 there will be registration and it will be possible to vaccinate,вЂќ said the investors. Thus, BioNTech and its American partner Pfizer will become, by all accounts, the first Western companies to launch a coronavirus vaccine on the market. According to Stryungman and Mothman, the company alone cannot resist the spread of the coronavirus. вЂњOne can only hope that vaccines from AstraZeneca, Moderna, and Curevac will be allowed soon,вЂќ investors said.
Strongman said that nearly 22,000 volunteers have so far taken part in the vaccine trials. вЂњNo one, to my knowledge, has so far been found to have serious side effects,вЂќ he stressed.
BioNTech published interim results of the third phase of trials of the new drug this week. According to her, the risk of contracting coronavirus with the use of the vaccine is more than 90% lower than without the vaccination. Together with Pfizer, she plans to file a registration request with the US Food and Drug Administration (FDA) next week.
As previously reported, the new drug belongs to a group of so-called gene vaccines that contain genetic information about the pathogen. BioNTech works primarily in the development of cancer immunotherapy.